本帖最后由 老马 于 2013-3-13 13:43 编辑
! \1 Q. h+ x9 W+ w& Z# P6 i7 Z* R6 x
健择（吉西他滨）+顺铂+阿瓦斯汀2 O) V$ X! Q8 V# ]9 q
Gemzar +Cisplatin + Avastin4 y# O( p" v( \& D! L+ U" N7 e& a+ W
http://annonc.oxfordjournals.org/content/21/9/1804.full) o) Q; I9 ^: `! Z1 G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 j; c5 Z+ t- _4 Z/ V$ WPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 }2 C, B7 D# `' ]+ {9 ^8 f
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ( W3 H$ p/ ]! D. z
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 228)
1 v0 Q ?4 K; f& y华为网盘附件：+ f9 i9 u0 P+ x; |
【华为网盘】ava.JPG
' t( g) z6 F3 L# T7 ] |
显身卡
